

a' Figure 14: Charts the results of experiments that demonstrate, in terms of percent hyperthermia, that vaccination with ORF'1 and ORF'2 of PCV-B enhances the level of protection in swine challenged with PCV-B (Percent hyperthermia: > 40.5°C, Control: not vaccinated and not challenged, ORF'1: vaccinated and challenged, ORF'2: vaccinated and challenged, ORF- :not vaccinated, challenged)

[Please delete a paragraph at page 9, lines 26-28, and substitute with the following paragraph:

an Figure 15: Charts the results of experiments that demonstrate, in terms of animal growth, that vaccination with ORF'1 and ORF'2 of PCV-B enhances the level of protection in swine challenged with PCV-B (Control: not vaccinated and not challenged, ORF'1: vaccinated and challenged, ORF'2: vaccinated and challenged, ORF- :not vaccinated, challenged).

IN THE CLAIMS

Please cancel claims 1 and 4, without prejudice or disclaimer.

In accordance with 37 C.F.R. § 1.121, please substitute for original claims 5, 6, 20 and 22, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

See B, > 90%
a' 5. (Amended) A vaccine comprising a nucleic acid having a nucleotide sequence with at least 90% sequence identity to SEQ ID No. 25 and an acceptable pharmaceutical vehicle, wherein said nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease ("PWD") circovirus.

6. (Amended) A vaccine according to claim 5, wherein said nucleotide sequence is SEQ ID No. 25.